Search Clinical Trials

Clinical Trials Search Results

The results of your search are listed below. To view the details of a trial or study, click on the see details >> link. Or start a new search.

Searched for: Multiple Myeloma

26 results total

A Multi-center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine

See details >>

Principal Investigator: William Bensinger, MD

Study Number: 2004.00

Tandem Autologous HCT / Nonmyeloablative Allogeneic HCT from HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients with High-Risk Multiple Myeloma

See details >>

Principal Investigator: Marco Mielcarek, MD

Study Number: 2070.00

A Phase II Study of Lenalidomide Following Allogeneic Stem Cell Transplant for Multiple Myeloma Patients Who Relapse or Have Disease Progression

See details >>

Principal Investigator: William Bensinger, MD

Study Number: 2161.00

Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant for Multiple Myeloma

See details >>

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: 2253.00

Combination Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma (PLD-BCD)

See details >>

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 6817

Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation

See details >>

Principal Investigator: Paul O'Donnell, MD, PhD

Study Number: 1667.00

A Multi-Center Phase III Study Comparing Nonmyeloablative Conditioning with TBI versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies

See details >>

Principal Investigator: Brenda Sandmaier, MD

Study Number: 1813.00

A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil

See details >>

Principal Investigator: David Maloney, MD, PhD

Study Number: 1898.00

A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial

See details >>

Principal Investigator: Brenda Sandmaier, MD

Study Number: 1938.00

Campath® (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies: a Multicenter Trial

See details >>

Principal Investigator: Brenda Sandmaier, MD

Study Number: 1959.00

Displaying first 10 of 26 total results. Click to view all 26 results.

Search Options

Select a disease from the list below:

Limit results to studies enrolling:
Both Adults & Pediatrics Adults Pediatrics

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.